Ruijin Hospital

Leukaemia classification and treatment

Ruijin’s haematology service and the Shanghai Institute of Hematology have longstanding work in leukaemia biology, classification and treatment. Leukaemia includes distinct diseases: marrow appearance, immunophenotype, chromosomes and molecular features refine the diagnosis and affect treatment expectations. The programme’s research tradition connects laboratory findings with clinical care.

Blood counts, marrow findings and residual disease help track response. In relapsed or refractory disease, reviewing the original subtype, responses and subsequent evolution supports assessment of further medicines, transplantation or other treatment.

Lymphoma: translating genetic subtypes into drug choices

In GUIDANCE-01, R-CHOP-X added targeted agents according to genetic subtype rather than giving every patient the same extra drug. Complete response was 88% versus 66% with standard R-CHOP, complementing the progression-free survival results above.

This is phase II evidence for newly diagnosed intermediate- or high-risk diffuse large B-cell lymphoma. Other lymphoma subtypes, relapsed disease and CAR-T treatment have their own evidence and assessment pathways.

CAR-T and support for intensive treatment

Ruijin reports clinical CAR-T work with multidisciplinary support. Suitability for a product or study depends on the disease, previous treatments and current health. Ask about assessment, cell collection, manufacturing, admission and observation after treatment.

Gastrointestinal surgery and minimally invasive techniques

Ruijin has a longstanding minimally invasive gastrointestinal surgery program. Minhua Zheng’s team has helped develop laparoscopic radical surgery for gastric and colorectal cancers, alongside clinical research, training and technical standards.

Surgical planning combines cancer clearance and lymph node management with disease extent, prior treatment and general fitness. Medical oncology, nutrition and recovery services contribute to the wider pathway.

Pancreatic surgery and translational research

Baiyong Shen’s pancreatic team combines longstanding clinical work, minimally invasive surgery and translational research. Its approach connects diagnosis, preoperative assessment, surgery, postoperative management and recurrence care. Vascular involvement, nutrition and biliary or pancreatic obstruction can all affect planning.

The team also studies approaches such as TCR-T and cancer vaccines. These are research programs; an individual patient’s access depends on an active study and eligibility.

Integrated breast cancer services

Ruijin’s breast center brings together breast surgery, radiation and medical oncology, pathology, radiology and ultrasound. Breast specialists including Kunwei Shen and Xiaosong Chen work alongside radiation experts such as Jiayi Chen.

Collaboration starts with imaging and tissue diagnosis and continues through treatment selection, nursing and rehabilitation. Tumor subtype and stage inform the sequence of surgery, medication and radiotherapy.

Endocrinology and endocrine tumor assessment

Endocrinology is a defining Ruijin specialty. Academician Guang Ning, Weiqing Wang and colleagues have longstanding work in diabetes, metabolism and adrenal disease. In adrenal lesions and related endocrine disorders, hormone assessment may be as important as imaging.

The service is also relevant when diabetes or treatment-associated endocrine abnormalities complicate cancer care, with collaboration among endocrine, surgical, imaging and laboratory teams.

Weili Zhao

Molecularly guided lymphoma treatment

Zhao’s team led GUIDANCE-01, a randomized phase II trial in 128 patients with newly diagnosed intermediate- or high-risk diffuse large B-cell lymphoma. Genetically matched additions to R-CHOP produced an 88% complete response rate versus 66% with R-CHOP alone. The practical focus is whether the lymphoma’s biology warrants a different regimen; treatment decisions still require confirmatory evidence and assessment of the patient’s fitness.

Junmin Li

AML in older patients or those unable to receive intensive chemotherapy

For patients unable to tolerate intensive chemotherapy, Li’s clinical work includes the Chinese cohort of a phase III trial of venetoclax plus low-dose cytarabine in previously untreated AML. This focus is relevant to balancing leukemia control against marrow suppression and infection risk, and selecting treatment that matches the patient’s physical condition.

Baiyong Shen

Minimally invasive pancreatic surgery and recovery

Shen’s team led PORTAL, a 268-patient phase III trial published in the BMJ in 2026. Median postoperative stay was 13 days after robotic pancreatoduodenectomy versus 16 after open surgery, although robotic surgery cost more. This expertise is relevant to resectable pancreatic-head or periampullary disease when weighing surgical burden, recovery and cost in an experienced center.

Costs & payment

Ask what the hospital estimate includes, deposits, additional charges and refund arrangements. Plan travel and living costs separately. Insurance coverage and direct billing require confirmation.

Language & records

Confirm interpreting for appointments, communication during treatment and the language of records. Our China coordination includes Chinese and English support; other languages need advance confirmation of availability and arrangements.

Campus, accommodation & caregivers

Consultations, tests and admission may take place at different sites. Distance, accessibility, caregiver rules and follow-up frequency all affect the itinerary and should be considered once the clinical plan is clearer.

Length of stay & returning home

Assessment, surgery, radiotherapy and cellular treatment have different schedules. Ask the hospital for the expected course, allowing for results and changes in the plan. Confirm readiness to return home with the clinical team.

Make your history easier to review

Organise treatments and key reports, help with necessary translation and bring the important questions to the clinician.

Find the appropriate clinical service

Enquire with the relevant specialty, follow up on record requirements and help clarify acceptance and appointments.

Coordinate the practical steps in China

Within the agreed scope, help with visa documentation, travel, arrival transport, accommodation and accompaniment.

Keep communication connected

Help organise consultation feedback, records for home and follow-up requirements, with continued contact as agreed.

Is the latest marrow report enough?

The team will also need the original classification, molecular results, treatment history and changes in residual disease. A dated record shows how the disease evolved and which treatments worked or stopped working.

Can I request one of the specialists featured here?

Tell us your preference and we can help enquire. The hospital confirms acceptance, the specialist’s involvement and who provides outpatient or inpatient care. It may also recommend another suitable clinician within the specialty.

Can I contact Chirona before choosing a hospital?

Yes. Share the diagnosis, treatment history and the decision you need help with. We can organise the questions to consider when comparing hospitals and explain the coordination available.

Does submitting records confirm treatment?

Submitting records starts the assessment. The hospital must confirm acceptance and clinical suitability and may require more information or in-person tests. Appointment confirmation, the treatment plan and costs should be clarified separately.